Effects of benzylpiperazine derivatives on the neurotoxicity of 3,4-methylenedioxymethamphetamine in rat brain.
Kenji Hashimoto, H Maeda, Tsuyoshi Goromaru
Brain Research September 1, 1992 DOI: 10.1016/0006-8993(92)91119-y (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Population | Rat brain |
| Interventions | 3 4-methylenedioxymethamphetamine (MDMA) p-nitrobenzylpiperazine p-chlorobenzylpiperazine 1-piperonylpiperazine |
| Measures | [3H]6-nitroquipazine binding to the 5-hydroxytryptamine (5-HT) transporter |
| Topics | Serotonin MDMA |
| Keywords | Brain Animals Rats, wistar N-methyl-3,4-methylenedioxyamphetamine Hydroxyindoleacetic acid Piperazines Designer drugs Male |
| Key points | Coadministration of several benzylpiperazines significantly attenuated MDMA-induced neurotoxicity in rat brain, even though these compounds were only weak inhibitors of [3H]6-nitroquipazine binding to the 5-HT transporter. The authors suggest the protection may involve a novel neuropharmacological effect other than 5-HT uptake inhibition. |
Abstract
The neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA) in rat brain was attenuated significantly by coadministration of several benzylpiperazines (p-nitrobenzylpiperazine, p-chlorobenzylpiperazine and 1-piperonylpiperazine), which were weak inhibitors for [3H]6-nitroquipazine binding to the 5-hydroxytryptamine (5-HT) transporter in rat brain. These results suggest that these benzylpiperazines may inhibit the MDMA-induced neurotoxicity by a novel neuropharmacological effect other than 5-HT uptake inhibition.
Citations in the library
Cited by 7
- Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types Therapeutic Drug Monitoring March 19, 2004
- The Role of Metabolism in 3,4-(±)-Methylenedioxyamphetamine and 3,4-(±)-Methylenedioxymethamphetamine (Ecstasy) toxicity Therapeutic Drug Monitoring March 19, 2004
- Effects of Intracerebroventricular Administration of 5-(Glutathion-S-yl)-α-methyldopamine on Brain Dopamine, Serotonin, and Norepinephrine Concentrations in Male Sprague-Dawley Rats Chemical Research in Toxicology 1996
- Qualitative Research of Online Drug Misuse Communities with Reference to the Novel Psychoactive Substances University of Hertfordshire Research Archive May 29, 2013
- MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions Psychedelics October 14, 2025
and 2 more in the library
Cites 9
- Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity Journal of Neuroscience August 1, 1988
- Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics 1987
- 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics September 1, 1987
- Antagonism of 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rat brain by 1-piperonylpiperazine. European Journal of Pharmacology September 1, 1992
- Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. Journal of Pharmacology and Experimental Therapeutics November 1, 1990
and 4 more in the library